Steven E. Schild
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Brain Metastases and Treatment 118
- Lung Cancer Diagnosis and Treatment 55
- Prostate Cancer Diagnosis and Treatment 49
- Oncology 103
- Lung Cancer Research Studies 48
- Co-authors
- Dirk Rades (251 shared papers)Alex A. Adjei (30 shared papers)Julian R. Molina (13 shared papers)Ping Yang (8 shared papers)Stephen D. Cassivi (2 shared papers)William W. Wong (86 shared papers)Theo Veninga (75 shared papers)Juergen Dunst (36 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (114 papers)Anticancer Research (71 papers)Strahlentherapie und Onkologie (51 papers)Cancer (38 papers)Journal of Thoracic Oncology (22 papers)
- Partner nations
- United StatesGermanyNetherlands
In The Last Decade
Steven E. Schild
633 papers receiving 31.1k citations
Steven E. Schild's Hit Papers
Peers
Comparison fields: 5 of 168
- Pulmonary and Respiratory Medicine 14.1k
- Oncology 8.1k
- Radiation 2.2k
- Genetics 2.3k
- Otorhinolaryngology 788
Countries citing papers authored by Steven E. Schild
This map shows the geographic impact of Steven E. Schild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven E. Schild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven E. Schild more than expected).
Fields of papers citing papers by Steven E. Schild
This network shows the impact of papers produced by Steven E. Schild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven E. Schild. The network helps show where Steven E. Schild may publish in the future.
Co-authors
The 25 scholars most cited alongside Steven E. Schild, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 645 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Hit paper breakdown → | 2008 | 2646 |
| 2 | Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Hit paper breakdown → | 2008 | 2482 |
| 3 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Hit paper breakdown → | 2015 | 1623 |
| 4 | Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2017 | 1114 |
| 5 | Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2022 | 1007 |
| 6 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 Hit paper breakdown → | 2021 | 756 |
| 7 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020 Hit paper breakdown → | 2019 | 722 |
| 8 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 Hit paper breakdown → | 2016 | 622 |
| 9 | Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial Hit paper breakdown → | 2016 | 600 |
| 10 | Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer Hit paper breakdown → | 2019 | 434 |
| 11 | 2015 | 416 | |
| 12 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 Hit paper breakdown → | 2018 | 402 |
| 13 | 1998 | 369 | |
| 14 | NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023 Hit paper breakdown → | 2023 | 339 |
| 15 | A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927) Hit paper breakdown → | 2015 | 325 |
| 16 | 2007 | 317 | |
| 17 | 2007 | 306 | |
| 18 | 2010 | 302 | |
| 19 | 2013 | 279 | |
| 20 | 2005 | 274 |
About Steven E. Schild
Steven E. Schild is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Otorhinolaryngology and Radiation, having authored 645 papers that have together received 32.1k indexed citations. Recurring topics across this work include Brain Metastases and Treatment (118 papers), Management of metastatic bone disease (97 papers), Lung Cancer Diagnosis and Treatment (55 papers), Prostate Cancer Diagnosis and Treatment (49 papers), Lung Cancer Research Studies (48 papers), Advanced Radiotherapy Techniques (48 papers), Glioma Diagnosis and Treatment (47 papers) and Head and Neck Cancer Studies (42 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (14.1k citations), Oncology (8.1k citations), Radiation (2.2k citations), Genetics (2.3k citations) and Otorhinolaryngology (788 citations). Steven E. Schild has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Dirk Rades, Alex A. Adjei, Julian R. Molina, Ping Yang, Stephen D. Cassivi, William W. Wong, Theo Veninga, Juergen Dunst, James R. Jett and Volker Rudat. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Anticancer Research, Strahlentherapie und Onkologie, Cancer and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.